Inotuzumab Ozogamicin and Mini-Hyper-CVD as Front-Line Therapy for Older Patients with B-Cell ALL


Inotuzumab Ozogamicin and Mini-Hyper-CVD as Front-Line Therapy for Older Patients with B-Cell ALL
Slides from a presentation at ASH 2015 and transcribed comments from a recent interview with Richard M Stone, MD (2/16/16)

Jabbour E et al. Frontline inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) for older patients with acute lymphoblastic leukemia (ALL). Proc ASH 2015;Abstract 83.

Dr Stone is Director of the Adult Leukemia Program at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School in Boston, Massachusetts.